Chevy Chase Trust Holdings LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Chevy Chase Trust Holdings LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 238,379 shares of the biopharmaceutical company’s stock after selling 3,375 shares during the period. Regeneron Pharmaceuticals accounts for 0.8% of Chevy Chase Trust Holdings LLC’s holdings, making the stock its 18th biggest holding. Chevy Chase Trust Holdings LLC’s holdings in Regeneron Pharmaceuticals were worth $250,594,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $26,000. Sachetta LLC raised its position in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $750.22 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The stock has a market capitalization of $82.44 billion, a PE ratio of 18.57, a P/E/G ratio of 2.89 and a beta of 0.15. The firm has a 50 day moving average of $905.64 and a two-hundred day moving average of $1,019.64.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.